Monoclonal Antibodies:
Monoclonal antibodies are a type of antibody manufactured by cloning identical immune cells. These antibodies are used in various therapeutic applications due to their high specificity and potency. Their ability to target specific cells and molecules has made them a preferred choice in the treatment of cancer, autoimmune diseases, and infectious diseases.
Bispecific Antibodies:
Bispecific antibodies possess two different binding specificities, enabling them to simultaneously target two different antigens or cells. This unique property makes them highly advantageous for targeted therapy and immunotherapy. Bispecific antibodies have gained significant attention in the treatment of cancer and autoimmune disorders.
Polyclonal Antibodies:
Polyclonal antibodies are a mixture of antibodies derived from different immune cells. They are widely used in research and diagnostics due to their ability to recognize a wide range of antigens. Polyclonal antibodies are generally employed in various immunoassays, such as ELISA and Western blot, to detect specific proteins or molecules.
Some of the key players operating in the antibody discovery market include:
- Eli Lilly and Company
- Abcam PLC
- Genentech, Inc.
- AstraZeneca PLC
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Pfizer Inc.
- Amgen Inc.
- Johnson & Johnson
- Novartis International AG
These market players are constantly focusing on research and development activities to enhance their product portfolios and gain a competitive edge in the antibody discovery market. They are also engaged in strategic collaborations, mergers, and acquisitions to expand their market presence and cater to the growing demand for antibody discovery.